Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Stabilization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    323 result(s) found for: Stabilization. Displaying page 1 of 17.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-001586-27 Sponsor Protocol Number: SOMCT01-C Start Date*: 2014-07-25
    Sponsor Name:SOM Innovation Biotech SL (SOM Biotech)
    Full Title: Study of SOM0226 in familial amyloid polyneuropathy (FAP) patients and asymptomatic carriers to evaluate protein stabilization activity
    Medical condition: Patients with familial amyloid polyneuropathy (FAP), asymptomatic carriers and healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004280-32 Sponsor Protocol Number: AG10-301 Start Date*: 2019-05-10
    Sponsor Name:Eidos Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial)
    Medical condition: Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) IE (Completed) PT (Completed) ES (Ongoing) NL (Completed) BE (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000213-30 Sponsor Protocol Number: IMA901-203 Start Date*: 2008-04-21
    Sponsor Name:immatics biotechnologies GmbH
    Full Title: Extension study to evaluate long-term-safety of IMA901 plus GM-CSF in advanced renal cell carcinoma patients who achieved a decrease in tumor load or stabilization of their disease after participat...
    Medical condition: This extension study will be conducted in men and women with advanced renal cell cancer (RCC) who achieved a decrease in tumor load or stabilization of their disease after participation in the core...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002350-31 Sponsor Protocol Number: CRFB002E2401 Start Date*: 2012-02-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab in...
    Medical condition: visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    14.1 10015919 - Eye disorders 10025415 Macular oedema PT
    14.1 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) SE (Completed) HU (Completed) AT (Completed) ES (Completed) CZ (Completed) SK (Completed) GR (Completed) PT (Completed) NL (Completed) PL (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-006791-12 Sponsor Protocol Number: Fx1A-201 Start Date*: 2008-04-02
    Sponsor Name:FoldRx Pharmaceuticals Limited
    Full Title: The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with Non-V30M Transthyretin Amyloidosis
    Medical condition: Non-V30M Transthyretin Amyloidosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002270-52 Sponsor Protocol Number: CIRIVA Start Date*: 2013-12-05
    Sponsor Name:Hospital Universitari de Girona Dr.Josep Trueta
    Full Title: Effects of cinacalcet versus conventional treatment on metabolism bone and vascular involvement in advanced chronic renal failure
    Medical condition: Bone's disorders and mineral metabolism and vascular involvement
    Disease: Version SOC Term Classification Code Term Level
    16.1 10047065 - Vascular disorders 10051753 Vascular calcification PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000749-21 Sponsor Protocol Number: 4.20 Start Date*: 2016-03-14
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: Botulinumtoxin A for emotional stabilization in borderline personality disorder
    Medical condition: Borderline personality disorder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019765-28 Sponsor Protocol Number: SP0993 Start Date*: 2011-02-08
    Sponsor Name:UCB BIOSCIENCES GmbH
    Full Title: A MULTICENTER, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, POSITIVE CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LACOSAMIDE (200 TO 600MG/DAY) TO CONTROLLED RELEASE CARBAMAZEPINE (400 TO 1200M...
    Medical condition: Epilepsy, partial onset or generalised tonic-clonic seizures.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) FI (Completed) SE (Completed) HU (Completed) ES (Completed) PT (Completed) PL (Completed) SK (Completed) GB (Completed) GR (Completed) IT (Completed) LV (Completed) LT (Completed) BG (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002859-34 Sponsor Protocol Number: CRFB002E2402 Start Date*: 2012-04-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, phase IIIb, open-label, randomized, activecontrolled, 3-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization-criteria-driven PRN dosing regimen w...
    Medical condition: visual impairment due to macular edema secondary to branch retinal occlusion (BRVO)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10025415 Macular oedema PT
    14.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    14.0 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) SE (Completed) HU (Completed) CZ (Completed) ES (Completed) SK (Completed) GR (Completed) NL (Completed) PT (Completed) PL (Completed) FR (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-005663-31 Sponsor Protocol Number: 12020 Start Date*: 2022-10-04
    Sponsor Name:AZIENDA OSPEDALIERA ORDINE MAURIZIANO DI TORINO
    Full Title: CARotid plaqUe StabilizatiOn and regression with evolocumab)
    Medical condition: atherosclerosis desead
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-006152-36 Sponsor Protocol Number: 1774 Start Date*: 2012-05-10
    Sponsor Name:Middelfart Rygsektor
    Full Title: Postoperative treatment with parathyroidea hormone Forteo® in patients undergoing posterolateral spinal fusion surgery. A prospektive and a randomized double-blinded, placebo-controlled study
    Medical condition: Spinal stenosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10041597 Spinal stenosis of lumbar region LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-002420-18 Sponsor Protocol Number: PTK787/ZK NET 2004 Start Date*: Information not available in EudraCT
    Sponsor Name:Prof. B. Wiedenmann, Klinik für Gastroenterologie, Charité, Campus Virchow
    Full Title: A prospective, non-randomized, non-controlled, open label, multicenter phase II Study: PTK 787/ ZK222584 in patients with advanced neuroendocrine tumors.
    Medical condition: This is a non-randomized, non-controlled, open label, multicenter phase II study to evaluate the efficacy and safety of PTK 787/ ZK 222584 in the treatment of patients with·progressive neuroendocri...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2009-017704-86 Sponsor Protocol Number: Dapto-Spondi-09 Start Date*: 2010-03-15
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Phase II clinical trial for the Staph. Aureus spondylodiscitis treatmen with daptomycin
    Medical condition: S. Aureus spondylodiscitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062691 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014444-11 Sponsor Protocol Number: RET04.09 Start Date*: 2009-08-10
    Sponsor Name:IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS
    Full Title: Functional and morphological retinal changes in diabetic macular edema treated with pegaptanib
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038901 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000788-30 Sponsor Protocol Number: 1.2022 Start Date*: 2023-04-13
    Sponsor Name:Uzdrowisko Kamień Pomorski S.A.
    Full Title: Evaluation of the effectiveness of Methocarbamol in the treatment of spasticity in people with spinal cord injury.
    Medical condition:
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002689-19 Sponsor Protocol Number: Allo-Relapse-2011 Start Date*: 2011-11-22
    Sponsor Name: [...]
    1.
    2. Haukeland University Hospital
    Full Title: TREATMENT OF RELAPSED ACUTE LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: DISEASE STABILIZATION THROUGH CHEMOTHERAPY, IMMUNOMODULATORY TREATMENT AND IMMUNOTHERAPY
    Medical condition: Allotransplanted patients with early acute leukemia repse (within 1 year after transplant)
    Disease:
    Population Age: Adults Gender:
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005643-22 Sponsor Protocol Number: AG10-304 Start Date*: 2022-02-07
    Sponsor Name:Eidos Therapeutics, Inc.
    Full Title: An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
    Medical condition: Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) IE (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004377-16 Sponsor Protocol Number: N01375 Start Date*: 2015-07-24
    Sponsor Name:UCB Japan Co. Ltd.
    Full Title: An Open-label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Levetiracetam Used as Monotherapy in Newly or Recently Diagnosed Epilepsy Patients Aged Older Than or Equal to 16...
    Medical condition: Focal Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-005856-32 Sponsor Protocol Number: RITULUP Start Date*: 2012-05-21
    Sponsor Name:Fundación Progreso y Salud
    Full Title: Comparison of the efficacy of two rituximab treatment regimens in patients with lupus nephropathy resistant to conventional treatment
    Medical condition: Long-term relapse after treatment of lupus nephritis (LN) resistant to conventional treatment
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004220-11 Sponsor Protocol Number: APL2-308 Start Date*: 2019-07-23
    Sponsor Name:Apellis Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 16:03:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA